PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics director Mary L. Smith exercised stock options for 15,834 shares of common stock at an exercise price of $42.95 per share and sold 15,834 shares in open-market transactions at $90.00 per share on July 9, 2026. The sales were effected pursuant to a written Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, she holds 21,813 shares of PTC Therapeutics common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,834 shares ($1,425,060)
Net Sell
6 txns
Insider
Smith Mary L.
Role
Director
Sold
15,834 shs ($1.43M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 5,834 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $42.95 | $430K |
| Sale | Common Stock | 10,000 | $90.00 | $900K |
| Exercise | Common Stock | 5,834 | $42.95 | $251K |
| Sale | Common Stock | 5,834 | $90.00 | $525K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 31,813 shares (Direct)
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Currently exercisable.
Key Figures
Shares sold: 15,834 shares
Sale price: $90.00 per share
Option exercise shares: 15,834 shares
+4 more
7 metrics
Shares sold
15,834 shares
Total common shares sold in open-market transactions on July 9, 2026
Sale price
$90.00 per share
Price for common stock sales on July 9, 2026
Option exercise shares
15,834 shares
Common shares acquired through stock option exercises on July 9, 2026
Option exercise price
$42.95 per share
Exercise or conversion price of stock options into common stock
Shares held after transactions
21,813 shares
Direct ownership of PTC Therapeutics common stock after July 9, 2026 trades
Net buy/sell shares
15,834 shares
Net-sell shares reported in transaction summary for this Form 4
Option expiration date
June 10, 2031
Expiration date for the stock options exercised on July 9, 2026
Key Terms
Rule 10b5-1 plan, Stock Option (Right to Buy, derivative security, open-market sale
4 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (Right to Buy financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What did PTC Therapeutics (PTCT) director Mary L. Smith report in this Form 4?
Mary L. Smith reported exercising options for 15,834 shares of PTC Therapeutics common stock at $42.95 per share and selling 15,834 shares at $90.00 per share on July 9, 2026, in open-market transactions.
What stock options did Mary L. Smith exercise in PTC Therapeutics (PTCT)?
She exercised stock options covering 15,834 shares of PTC Therapeutics common stock with an exercise price of $42.95 per share, described as an exercise or conversion of a derivative security on July 9, 2026.
Were Mary L. Smith’s PTC Therapeutics (PTCT) stock sales under a Rule 10b5-1 plan?
Yes. A footnote states that the transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Mary L. Smith on November 11, 2025, indicating the trades were pre-arranged under that plan.
What is the net effect of Mary L. Smith’s July 9, 2026 trades in PTC Therapeutics (PTCT)?
The Form 4 summary shows 15,834 shares sold and 15,834 shares exercised, resulting in net-sell shares of 15,834 when considering open-market transactions versus exercises, with remaining direct ownership of 21,813 shares.